Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan;22(1):75-76.
doi: 10.7861/clinmed.rib.22.1.1.

Research in brief: Empagliflozin for patients with heart failure and preserved ejection fraction

Rajan S Pooni  1 , Tevfik F Ismail  2
Affiliations
Comment

Research in brief: Empagliflozin for patients with heart failure and preserved ejection fraction

Rajan S Pooni et al. Clin Med (Lond). 2022 Jan.
No abstract available

Keywords: empagliflozin; heart failure; preserved ejection fraction.

PubMed Disclaimer

Comment on

  • Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca HP, Choi DJ, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Preserved Trial Investigators. Anker SD, et al. N Engl J Med. 2021 Oct 14;385(16):1451-1461. doi: 10.1056/NEJMoa2107038. Epub 2021 Aug 27. N Engl J Med. 2021. PMID: 34449189 Clinical Trial.

References

    1. Anker SD, Butler J, Filippatos G, et al. . Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–61. - PubMed
    1. McDonagh TA, Metra M, Adamo M, et al. . 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–726. - PubMed
    1. Solomon SD, McMurray JJV, Anand IS, et al. . Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609–20. - PubMed
    1. Zelniker TA, Wiviott SD, Raz I, et al. . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31–9. - PubMed
    1. Packer M, Anker SD, Butler J, et al. . Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413–24. - PubMed